| Literature DB >> 25400122 |
Kenichiro Kobayashi1, Naoyuki Miyagawa, Kazumasa Mitsui, Masaki Matsuoka, Yasuko Kojima, Hiroyuki Takahashi, Kaori Ootsubo, Junichi Nagai, Hitomi Ueno, Takeshi Ishibashi, Sara Sultana, Yoko Okada, Shingo Akimoto, Hajime Okita, Kimikazu Matsumoto, Hiroaki Goto, Nobutaka Kiyokawa, Akira Ohara.
Abstract
We report a 10-year-old male with relapsing Ph-like acute lymphoblastic leukemia (ALL) bearing ATF7IP/PDGFRB translocation. He was refractory to conventional therapy, and was finally treated with single-agent second-generation TKI dasatinib. The therapeutic response was prompt, with the disappearance of minimum residual disease (MRD) based on genomic PCR analysis within 3 months, and he has maintained complete molecular remission for 12 months. This case report describes an early-phase response to TKI monotherapy on Ph-like ALL, and technical tips for MRD monitoring on long-term follow-up.Entities:
Keywords: MRD; PDGFRB fusion; Ph-like ALL; TKI; genomic PCR
Mesh：
Substances：
Year: 2014 PMID： 25400122 DOI： 10.1002/pbc.25327
Source DB: PubMed Journal: Pediatr Blood Cancer ISSN： 1545-5009 Impact factor: 3.167